摘要
Objective: To evaluate long-term outcomes of inebilizumab treatment in AQP4+ NMOSD participants from the N-MOmentum trial with a history of immunosuppressant therapy as compared to those without. Background: Inebilizumab (anti-CD19 B-cell-depleting antibody) is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults seropositive for aquaporin-4 antibody (AQP4+). Immunosuppressants were prohibited during the N-MOmentum pivotal trial, although many participants had a history of immunosuppressant therapy before enrolment. Design/Methods: N-Momentum (NCT02200770) was a 28-week-randomized-phase-2/3 trial of inebilizumab vs placebo, with an optional Open-Label-Extension (OLE) (>2 years). Immunosuppressant medication for the prevention or treatment of NMOSD relapses was allowed prior to dosing on Day 1. In this analysis, AQP4+ participants who received inebilizumab (through OLE) were grouped by no history of immunosuppression therapy beyond treatment of acute NMOSD attacks (naïve), or prior azathioprine (AZA) and/or mycophenolate mofetil (MMF) therapy. Outcomes included annualized relapse and hospitalization rates, as well as safety assessments. Results: Among inebilizumab participants, 94 received prior-AZA/MMF and 103 were immunosuppressant-naïve. The total patient-years of inebilizumab treatment in the prior-AZA/MMF group was 300.35 and for immunosuppressant-naïve participants, 335.7. The annualized relapse rate (95% confidence interval [CI]) for participants with prior-AZA/MMF was 0.11 (0.07, 0.17), compared to 0.08 (0.05, 0.14) for naïve. The annualized NMOSD-related inpatient hospitalization rate (annualized rate [95% CI]) for prior-AZA/MMF was 0.15 (0.08, 0.27), and 0.12 (0.06, 0.22) for naïve. The percentage of participants with ≥1 study drug-related-treatment-emergent-adverse-event (TEAE) was 30.9% (29/94) in prior-AZA/MMF and 46.6% (49/103) of naïve; 4.3% (4) of prior-AZA/MMF and 5.8% (6) of immunosuppressant-naïve reported ≥1 study drug-related-serious-adverse-event. Most adverse events were infection-related for both groups; (72.3% (68/94) for prior-AZA/MMF and 76.7% (79/94) for naïve). Conclusions: This post hoc analysis evaluating long-term outcomes of inebilizumab in AQP4+ NMOSD participants treated with prior AZA/MMF therapy demonstrated a similar efficacy and safety profile as participants without prior immunosuppressant therapy. Disclosure: The institution of Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe PC (MTPC). The institution of Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aarhus University. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Paul has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CELGENE. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ACRELION. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Viela Bio. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizter. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck Serono. The institution of Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Marignier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Marignier has received personal compensation in the range of $0-$499 for serving as a Consultant for ALEXION. Dr. Marignier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ROCHE. Dr. Marignier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HORIZON THERAPEUTICS. Dr. Marignier has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Lindsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lindsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Banner Life Sciences. Dr. Lindsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Lindsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mapi. Dr. Lindsey has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Teva. The institution of Dr. Lindsey has received research support from Genentech. Dr. Kim has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aprilbio, HanAll BioPharma, Viela Bio. Dr. Kim has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion, Biogen, Celltrion, Eisai, Merck Serono, Novartis, Sanofi Genzyme, Teva-Handok. Dr. Kim has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Multiple Sclerosis Journal, Journal of Clinical Neurology. Dewei She has received personal compensation for serving as an employee of Horizon Therapeutics. Dr. Cimbora has received personal compensation for serving as an employee of Viela Bio. Dr. Cimbora has received stock or an ownership interest from Viela Bio. Dr. Patterson has received personal compensation for serving as an employee of Hospital of the University of Pennsylvania. Dr. Patterson has stock in Horizon Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Atara. The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Autobahn. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avotres. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gossamer Bio. Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuron23. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal/Sandoz. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Therini. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. The institution of Dr. Cree has received research support from Genentech. Dr. Cree has received publishing royalties from a publication relating to health care.